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Summary 
Background Microarray expression proﬁ ling classiﬁ es breast cancer into ﬁ ve molecular subtypes: luminal A, luminal B, 
basal-like, HER2, and normal breast-like. Three microarray-based single sample predictors (SSPs) have been used to 
deﬁ ne molecular classiﬁ cation of individual samples. We aimed to establish agreement between these SSPs for 
identiﬁ cation of breast cancer molecular subtypes.
Methods Previously described microarray-based SSPs were applied to one in-house (n=53) and three publicly available 
(n=779) breast cancer datasets. Agreement was analysed between SSPs for the whole classiﬁ cation system and for the 
ﬁ ve molecular subtypes individually in each cohort. 
Findings Fair-to-substantial agreement between every pair of SSPs in each cohort was recorded (κ=0·238–0·740). Of 
the ﬁ ve molecular subtypes, only basal-like cancers consistently showed almost-perfect agreement (κ>0·812). The 
proportion of cases classiﬁ ed as basal-like in each cohort was consistent irrespective of the SSP used; however, the 
proportion of each remaining molecular subtype varied substantially. Assignment of individual cases to luminal A, 
luminal B, HER2, and normal breast-like subtypes was dependent on the SSP used. The signiﬁ cance of associations 
with outcome of each molecular subtype, other than basal-like and luminal A, varied depending on SSP used. 
However, diﬀ erent SSPs produced broadly similar survival curves.
Interpretation Although every SSP identiﬁ es molecular subtypes with similar survival, they do not reliably assign the 
same patients to the same molecular subtypes. For molecular subtype classiﬁ cation to be incorporated into routine 
clinical practice and treatment decision making, stringent standardisation of methodologies and deﬁ nitions for 
identiﬁ cation of breast cancer molecular subtypes is needed.
Funding Breakthrough Breast Cancer, Cancer Research UK.
Introduction
Breast cancers are a diverse and heterogeneous group of 
diseases, and clinicopathological features and the status 
of oestrogen receptor and HER2 guide treatment of 
patients. However, these variables are not suﬃ  cient for 
individualisation of therapy. Microarray-based gene 
expression proﬁ ling has led to a paradigm shift in the 
way breast cancer is perceived, and has shown 
conclusively that breast cancer is not a single disease at 
the molecular level.1–6 The molecular heterogeneity of 
breast cancer and its implications are gradually being 
incorporated into clinical trial design,7  and treatment 
strategies are being tailored to speciﬁ c subgroups of 
patients with breast cancer whose tumours have 
particular molecular aberrations (eg, trastuzumab or 
lapatinib for women with HER2-positive disease). 
Microarray-based gene expression proﬁ ling has led to a 
working model for a breast cancer molecular taxonomy,1–3 
which has become widely used. Breast cancers can be 
classiﬁ ed by hierarchical cluster analysis, using an 
intrinsic gene list, into one of ﬁ ve molecular subtypes: 
luminal A, luminal B, basal-like, HER2, and normal 
breast-like.1–5,8 However, this approach can only be applied 
retrospectively to suﬃ  ciently sized cohorts of patients.8 
An alternative strategy for classiﬁ cation of single samples 
into one of these molecular subtypes is the single sample 
predictor (SSP),3–5 which is based on similarities between 
a given case and molecular subtype centroids.3,4 Breast 
cancer molecular subtypes identiﬁ ed by these approaches 
have been suggested to have distinct clinical 
presentations,9 sites of relapse,10 histological features,11 
responses to chemotherapy,5,12 and outcomes.2,4,8,13 
For consistent and clinically applicable molecular 
subtype assignment of breast cancers, a standardised 
methodology with reproducible results is fundamental.13 
In the past 10 years, ﬁ ve distinct intrinsic gene lists1–5 and 
three diﬀ erent SSPs3–5 have been described to classify 
breast cancers into molecular subtype classes. Molecular 
subtypes identiﬁ ed in separate studies with diﬀ erent 
SSPs are assumed to be similar, if not identical, with 
respect to their clinical, biological, and prognostic 
characteristics (ie, luminal A cancers in study A identiﬁ ed 
by the SSP-a are synonymous with luminal A cancers in 
study B identiﬁ ed by the SSP-b). Crucially, however, the 
validity of this assumption has not been tested 
systematically. Nevertheless, some researchers have 
advocated that this molecular taxonomy should be used 
to design clinical studies6,14 and to “guide decision-making 
regarding therapy”.14 
The aims of this study were to assess the clinical 
usefulness of SSPs by establishing agreement between 
diﬀ erent methods of breast cancer molecular subtype 
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assignment (ie, do diﬀ erent SSPs assign the same 
patients to the same molecular subtype?), and to ascertain 
whether each SSP identiﬁ es molecular subtypes with 
similar associations with outcome. To address these 
objectives, we analysed a cohort of consecutive invasive 
ductal carcinomas of no special type of histological grade 
III, which were microdissected to minimise the eﬀ ect of 
varying amounts of stromal contamination,15 and three 
cohorts of breast cancer samples in the public 
domain.16–18
Methods
Sample collection
We obtained 64 anonymised samples of consecutively 
accrued grade III invasive ductal carcinomas of no special 
type from Hospital La Paz, Madrid, Spain. Details of this 
cohort are described elsewhere.15 We deﬁ ned HER2 status 
with US Food and Drug Administration (FDA)-approved 
methods for immuno histochemistry and dual-colour 
ﬂ uorescence in-situ hybridisation (FISH) as previously 
described,19 and we scored status according to guidelines 
of the American Society of Clinical Oncology and College 
of American Pathologists (webappendix pp 1–4).20 We 
micro dissected representative frozen sections of tumours 
to ensure a consistent proportion of at least 90% tumour 
cells, and we extracted RNA with Trizol (Invitrogen, 
Paisley, UK) as previously described.15 53 cases produced 
suﬃ  cient RNA of optimum quality and underwent gene-
expression proﬁ ling with the Illumina Human WG6 
version 2 array (Illumina Inc, San Diego, USA). Raw 
gene-expression values were robust-spline normalised 
with the lumi Bioconductor package21 in R. Gene 
expression data are publicly available at ArrayExpress 
(ref E-TABM-543). A detailed description of the micro-
array analysis methods is provided in the webappendix 
(pp 1–4). The local research ethics committees approved 
this project.
We analysed breast cancers from the publicly available 
NKI-295 (n=295),16 Wang (n=286),17 and TransBig (n=198)18 
datasets for molecular subtype classes and association 
with outcome. We obtained normalised microarray-based 
gene-expression data and clinical ﬁ ndings from the 
internet or public repositories (NKI-295,22 Wang 
[GEO:GSE2034], TransBig [GEO:GSE7390]). Details for 
the cohorts are provided in the webappendix (p 5).
Procedures
Methods related to mapping of centroid/SSP gene lists 
and breast cancer datasets and molecular subtype 
assignment are described in detail in the webappendix 
(pp 1–4). We have attempted to follow details for SSP 
analysis described in published work.3–5 To minimise the 
need to make assumptions, we tested several methods of 
gene and probe annotations and of handling of multiple 
probes for the same gene (webappendix pp 1–4). We used 
the method that most accurately reproduced the 
Grade III invasive ductal carcinomas (n=53) NKI-295 dataset (n=295) Wang dataset (n=286) TransBig dataset (n=198)
No cut-oﬀ Cut-oﬀ  <0·1* No cut-oﬀ Cut-oﬀ  <0·1* No cut-oﬀ Cut-oﬀ  <0·1* No cut-oﬀ Cut-oﬀ  <0·1*
Sorlie SSP 
Basal-like 13 (25%) 13 (25%) 47 (16%) 46 (16%) 49 (17%) 46 (16%) 30 (15%) 30 (15%)
HER2 0 0 46 (16%) 39 (13%) 9 (3%) 7 (2%) 11 (6%) 7 (4%)
Luminal A 7 (13%) 6 (11%) 96 (33%) 68 (23%) 104 (36%) 85 (30%) 64 (32%) 43 (22%)
Luminal B 33 (62%) 29 (55%) 77 (26%) 50 (17%) 124 (43%) 100 (35%) 90 (45%) 65 (33%)
Normal breast-like 0 0 29 (10%) 15 (5%) 0 0 3 (2%) 0 
Unclassiﬁ ed NA 5 (9%) NA 77 (26%) NA 48 (17%) NA 53 (27%)
Hu SSP         
Basal-like 14 (26%) 12 (23%) 56 (19%) 53 (18%) 53 (19%) 47 (16%) 40 (20%) 31 (16%)
HER2 8 (15%) 0 37 (13%) 32 (11%) 42 (15%) 21 (7%) 30 (15%) 15 (8%)
Luminal A 31 (58%) 14 (26%) 133 (45%) 127 (43%) 171 (60%) 152 (53%) 119 (60%) 110 (56%)
Luminal B 0 0 48 (16%) 47 (16%) 19 (7%) 17 (6%) 9 (5%) 9 (5%)
Normal breast-like 0 0 21 (7%) 19 (6%) 1 (<1%) 0 0 0 
Unclassiﬁ ed NA 27 (51%) NA 17 (6%) NA 49 (17%) NA 33 (17%)
Parker SSP         
Basal-like 13 (24%) 13 (24%) 48 (16%) 47 (16%) 54 (19%) 52 (18%) 41 (21%) 41 (21%)
HER2 0 0 54 (18%) 53 (18%) 15 (5%) 15 (5%) 11 (6%) 11 (6%)
Luminal A 4 (8%) 3 (6%) 90 (31%) 89 (30%) 65 (23%) 61 (21%) 63 (32%) 63 (32%)
Luminal B 36 (68%) 35 (66%) 78 (26%) 77 (26%) 139 (49%) 138 (48%) 75 (38%) 73 (37%)
Normal breast-like 0 0 25 (8%) 24 (8%) 13 (5%) 11 (4%) 8 (4%) 7 (4%)
Unclassiﬁ ed NA 2 (4%) NA 5 (2%) NA 9 (3%) NA 3 (2%)
Data are n (%). SSP=single sample predictor. NA=not assessable because all samples are classiﬁ ed. *Correlation with centroid/SSP <0·1. 
Table 1: Molecular subtype classiﬁ cations of breast cancers 
See Online for webappendix
For the R code used see http://
rock.icr.ac.uk/collaborations/
Mackay/
For ArrayExpress see http://
www.ebi.ac.uk/microarray-as/ae/
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previously published23,24 molecular subtype assignments 
of the NKI-295 dataset cancers with SSPs described by 
Sorlie and colleagues3 and Hu and coworkers.4 In brief, 
annotations of centroid/SSP gene lists and breast cancer 
datasets were comprehensively updated and mapped to 
build 36 of the human genome (Ensembl assembly 54); 
annotation overlays were done with Human Genome 
Organisation (HUGO) gene symbols. We averaged 
multiple probes that identiﬁ ed a gene in a centroid/SSP 
gene list. To deﬁ ne whether a tumour pertained to the 
basal-like, HER2, luminal A, luminal B, or normal breast-
like molecular subtype class, we correlated the gene 
expression of each tumour with 500 gene centroids by 
Sorlie and colleagues3 (Sorlie’s SSP), 306 gene centroids by 
Hu and coworkers4 (Hu’s SSP), and 50 gene centroids 
(PAM50) by Parker and colleagues5 (Parker’s SSP).  
A Sweave document is provided in the webappendix 
(pp 62–76).
Statistical analysis
Cohen’s κ coeﬃ  cient25 was used to measure agreement 
between molecular subtype assignments. We judged 
values of 0·01–0·20 slight agreement, 0·21–0·40 fair 
agreement, 0·41–0·60 moderate agreement, 0·61–0·80 
substantial agreement, and 0·81–0·99 almost-perfect 
agreement.26 Survival curves were calculated by the 
Kaplan-Meier method and compared with the log-rank 
test. We applied a proportional-hazards model by Cox’s 
regression analysis to estimate hazard ratios and 95% CI 
for overall survival (NKI-295 and TransBig datasets) and 
metastasis-free survival (Wang cohort, in addition to 
NKI-295 and TransBig cohorts). We ﬁ tted SSPs as 
categorical variables—ie, we made no assumption of a 
trend across subtypes. In a multivariate analysis, tumour 
size was ﬁ tted as continuous variable, tumour grade was 
ﬁ tted as an ordinal variable, and oestrogen-receptor 
status and nodal status were ﬁ tted as binary variables 
(positive vs negative). We judged a two-tailed p<0·05 
signiﬁ cant. 
We undertook a combined analysis to assess the 
performance of SSPs simultaneously in all datasets. In 
this case, we stratiﬁ ed the Cox model by dataset; this 
process allowed baseline hazard functions to diﬀ er in 
each dataset but constrained the estimated hazard ratios 
to be the same across the datasets. This technique is 
similar to meta-analysis, in which eﬀ ects are estimated 
independently within datasets and then combined across 
datasets. It reduces the eﬀ ect of confounding on hazard 
ratio estimates caused by inherent diﬀ erences in 
prognosis between diﬀ erent datasets but, similar to meta-
Sorlie SSP Hu SSP
Basal Luminal A Luminal B Normal HER2 κ (95% CI) Basal Luminal A Luminal B Normal HER2 κ (95% CI)
53 grade III invasive ductal carcinomas
Hu SSP 0·274 (0·173–0·375) ··
Basal 13 0 1 0 0 ·· ·· ·· ·· ·· ·· ··
Luminal A 0 7 24 0 0 ·· ·· ·· ·· ·· ·· ··
Luminal B 0 0 0 0 0 ·· ·· ·· ·· ·· ·· ··
Normal 0 0 0 0 0 ·· ·· ·· ·· ·· ·· ··
HER2 0 0 8 0 0 ·· ·· ·· ·· ·· ·· ··
Parker SSP 0·740 (0·566–0·913) 0·238 (0·148–0·328)
Basal 13 0 0 0 0 ·· 13 0 0 0 0 ··
Luminal A 0 2 2 0 0 ·· 0 4 0 0 0 ··
Luminal B 0 5 31 0 0 ·· 1 27 0 0 8 ··
Normal 0 0 0 0 0 ·· 0 0 0 0 0 ··
HER2 0 0 0 0 0 ·· 0 0 0 0 0 ··
NKI-295 dataset
Hu SSP 0·532 (0·462–0·603) ··
Basal 45 0 3 1 7 ·· ·· ·· ·· ·· ·· ··
Luminal A 1 81 24 18 9 ·· ·· ·· ·· ·· ·· ··
Luminal B 0 15 32 0 1 ·· ·· ·· ·· ·· ·· ··
Normal 1 0 4 10 6 ·· ·· ·· ·· ·· ·· ··
HER2 0 0 14 0 23 ·· ·· ·· ·· ·· ·· ··
Parker SSP 0·528 (0·456–0·601) 0·656 (0·592–0·721)
Basal 46 0 0 0 2 ·· 45 2 0 1 0 ··
Luminal A 0 57 13 14 6 ·· 0 84 2 4 0 ··
Luminal B 0 33 41 3 1 ·· 4 32 41 0 1 ··
Normal 1 5 4 11 4 ·· 0 10 1 13 1 ··
HER2 0 1 19 1 33 ·· 7 5 4 3 35 ··
(Continues on next page)
For Ensembl see http://www.
ensembl.org
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analysis, it uses all co horts in one analysis, maximising 
the power to detect eﬀ ects.
Statistical analyses were done with R version 2.9.0 and 
SPSS version 11.5. 
Role of the funding source
The sponsors had no role in study design, data collection, 
data analysis, data interpretation, writing of the report, or 
in the decision to submit for publication. BW, AM, and 
JSR-F had full access to raw data. BW, AM, MD, AA, 
and JSR-F took ﬁ nal responsibility for the decision to 
submit the report for publication.
Results
First, we sought to deﬁ ne the exact methods used 
previously to classify breast cancers according to three 
SSPs. In the SSP analysis process, parameters and 
procedures were not described in suﬃ  cient detail in the 
original publications.3–5 To minimise the need to make 
assumptions on methodology for assignment of 
molecular subtypes and to reduce inconsistencies in 
analysis methods, we aimed to reproduce the molecular 
subtype predictions of the NKI-295 dataset of breast 
cancers, which were previously classiﬁ ed into molecular 
subtypes by the Sorlie or Hu SSPs (webappendix 
pp 6–8).23,24 Agreement in molecular subtype assignment 
between the methods tested here and those previously 
published was 0·715–0·940 and depended on three 
factors: (1) use of diﬀ erent gene annotations for mapping 
of centroid/SSP gene lists and datasets; (2) use of all 
probes identifying a gene versus averaging of multiple 
probes representing the same gene to establish 
correlations to a centroid/SSP gene list; and (3) inclusion 
or exclusion of unclassiﬁ ed cases with a correlation less 
than 0·1 to any centroid.3,23 This cut-oﬀ  was described by 
Sorlie and colleagues3 as a conservative approach to 
include only cases with a strong correlation to a molecular 
subtype (webappendix pp 1–4, 9). In view of the scarcity 
of detailed guidelines for microarray data processing and 
SSPs and the eﬀ ect of the methodology used for 
assignment of cases, our ﬁ ndings indicate that breast 
cancer molecular subtype classiﬁ cations done by other 
investigators with the same datasets might not necessarily 
reproduce those originally described.
Sorlie SSP Hu SSP
Basal Luminal A Luminal B Normal HER2 κ (95% CI) Basal Luminal A Luminal B Normal HER2 κ (95% CI)
(Continued from previous page)
Wang dataset
Hu SSP 0·459 (0·394–0·524) ··
Basal 48 0 4 0 1 ·· ·· ·· ·· ·· ·· ··
Luminal A 0 103 66 0 2 ·· ·· ·· ·· ·· ·· ··
Luminal B 0 1 18 0 0 ·· ·· ·· ·· ·· ·· ··
Normal 1 0 0 0 0 ·· ·· ·· ·· ·· ·· ··
HER2 0 0 36 0 6 ·· ·· ·· ·· ·· ·· ··
Parker SSP 0·439 (0·355–0·522) 0·393 (0·331–0·455)
Basal 46 0 6 0 2 ·· 50 0 0 0 4 ··
Luminal A 0 47 18 0 0 ·· 0 64 0 0 1 ··
Luminal B 0 55 82 0 2 ·· 1 99 19 0 20 ··
Normal 3 2 6 0 2 ·· 2 8 0 1 2 ··
HER2 0 0 12 0 3 ·· 0 0 0 0 15 ··
TransBig dataset
Hu SSP 0·404 (0·328–0·480) ··
Basal 30 0 10 0 0 ·· ·· ·· ·· ·· ·· ··
Luminal A 0 63 51 3 2 ·· ·· ·· ·· ·· ·· ··
Luminal B 0 1 8 0 0 ·· ·· ·· ·· ·· ·· ··
Normal 0 0 0 0 0 ·· ·· ·· ·· ·· ·· ··
HER2 0 0 21 0 9 ·· ·· ·· ·· ·· ·· ··
Parker SSP 0·488 (0·388–0·587) 0·475 (0·398–0·553)
Basal 30 0 10 0 1 ·· 38 0 0 0 3 ··
Luminal A 0 41 21 0 1 ·· 0 63 0 0 0 ··
Luminal B 0 22 49 0 4 ·· 2 48 9 0 16 ··
Normal 0 1 4 3 0 ·· 0 8 0 0 0 ··
HER2 0 0 6 0 5 ·· 0 0 0 0 11 ··
SSP=single sample predictor.
Table 2: Agreement between single sample predictors for molecular subtype assignments 
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The method that most accurately reproduced the 
reported23,24 molecular subtype assignments of NKI-295 
breast cancers (κ 0·912 [95% CI 0·875–0·949] for 
Sorlie’s SSP and 0·897 [0·896–0·938]) for Hu’s SSP; 
webappendix p 9) was chosen to deﬁ ne subtypes in 
subsequent analyses (ie, HUGO gene symbol 
annotations for SSP and dataset mapping and averaging 
of multiple probes matching a gene in a centroid/SSP 
gene list; webappendix pp 1–4). 
We retrieved assignments for NKI-295 tumours 
undertaken previously;23,24 only moderate agreement was 
seen between assignments made with the Sorlie3,23 and 
Hu4,12 SSPs when all cases were included (κ 0·527 
[0·456–0·597]). Substantial agreement was noted (κ 0·646 
[0·565–0·727]) after exclusion of 109 unclassiﬁ ed cases 
with weak correlation (<0·1) to any centroids by Sorlie 
and colleagues3,23 (webappendix pp 6–8). This ﬁ nding 
suggests that, overall, concordance between diﬀ erent 
SSPs for classiﬁ cation of breast cancers into molecular 
subtypes might only be modest. 
We next ascertained molecular subtype classes (table 1) 
and agreement between subtype assignments produced 
by the three distinct SSPs in the four breast cancer 
cohorts (table 2, webappendix pp 10–20). We recorded 
only fair-to-moderate agreement between classiﬁ cations 
provided by Sorlie’s and Hu’s SSPs (κ 0·274–0·532; 
table 2), moderate-to-substantial agreement between 
Sorlie’s and Parker’s SSPs (κ 0·439–0·740, table 2), and 
fair-to-substantial agreement between Hu’s and Parker’s 
SSPs (κ 0·238–0·656; table 2, webappendix pp 19–20).  
Tables 1 and 2 show that in all four cohorts, the number 
of cases assigned to HER2, luminal A, luminal B, and 
normal breast-like molecular subtypes diﬀ ered 
remarkably, as did the number of unclassiﬁ ed cases with 
a correlation less than 0·1 to any centroid (table 1, 
ﬁ gures 1–3, webappendix pp 31–37). Of the ﬁ ve molecular 
subtypes, only the proportion of basal-like tumours was 
similar between the three distinct SSPs tested.
None of the microdissected grade III invasive ductal 
carcinomas with a tumour-cell content of at least 90% 
Figure 1: Molecular subtype classiﬁ cation of NKI-295 breast cancers and overall survival of patients assigned to molecular substypes according to three single sample predictors
ER=oestrogen receptor. SSP=single sample predictor.
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was assigned to the normal breast-like class by any of 
the three SSPs (table 1). Seven of 13 HER2-ampliﬁ ed 
grade III invasive ductal carcinomas—as indicated by 
immuno histochemistry and FISH—were assigned to 
the molecular HER2 subtype group with Hu’s SSP, 
whereas the Sorlie and Parker SSPs assigned all HER2-
ampliﬁ ed cases to the luminal B subtype class 
(webappendix p 10). 
We tested agreement between diﬀ erent SSPs for 
classiﬁ cation of molecular subtypes individually, for each 
dataset. Agreement between HER2, luminal A, and 
luminal B subtypes classiﬁ ed with Sorlie’s, Hu’s, or 
Parker’s SSPs was generally only fair to moderate (table 3, 
webappendix p 21). In the Wang and TransBig cohorts, 
concordance in assignment of tumours to luminal B 
class between Sorlie’s and Hu’s SSPs, and between Hu’s 
and Parker’s SSPs, was only slight. Almost-perfect 
concordance was noted only for classiﬁ cation of the 
basal-like subtype by all three SSPs (κ 0·812–1·000), 
which was also recorded when unclassiﬁ ed cases were 
included in the analysis (webappendix p 21). Our ﬁ ndings 
show that, for assignment of HER2, luminal A, luminal 
B, and normal breast-like subtype classes, agreement 
between distinct SSPs is only modest, but concordance 
for basal-like class is high. 
To assess whether each SSP identiﬁ es molecular 
subtypes with similar prognostic implications, tumours 
of patients in the NKI-295, Wang, and TransBig cohorts 
were classiﬁ ed into molecular subtype groups and their 
association with outcome was calculated by Kaplan-Meier 
analysis. Independent of the SSP used, molecular 
classiﬁ cation was associated signiﬁ cantly with overall 
survival (ﬁ gure 1) and metastasis-free survival 
(webappendix p 31) in the NKI-295 dataset and with 
metastasis-free survival in the Wang dataset (no 
information on overall survival is available publicly for 
this cohort; ﬁ gure 2). These associations were also noted 
when unclassiﬁ ed cases (ie, correlation <0·1 to any 
centroid/SSP gene list) were included in the analysis, 
with the exception of the assignment by Sorlie’s SSP in 
the Wang dataset (webappendix pp 32–34). In the 
TransBig data set, molecular subtypes were only associated 
signiﬁ cantly with overall survival (ﬁ gure 3) and 
metastasis-free survival (webappendix pp 35–37) when 
classiﬁ cations were made with Hu’s SSP; similar ﬁ ndings 
were seen when un classiﬁ ed cases were included in the 
Figure 2: Molecular subtype classiﬁ cation of Wang breast cancers and metastasis-free survival of patients assigned to molecular subtypes according to three single sample predictors
ER=oestrogen receptor. SSP=single sample predictor.
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analysis. Importantly, the number and identity of cases 
assigned to molecular sub types in each cohort diﬀ ered by 
the SSP used, with the exception of basal-like subtype 
(ﬁ gures 1–3, tables 1 and 2).
Multivariate Cox’s hazard analysis—including histo-
logical grade, tumour size, lymph node status, and 
oestrogen receptor status—showed that, in the NKI-295 
dataset, molecular subtypes only added independent 
prognostic information when assigned by the Parker SSP 
for overall survival and by the Hu and Parker SSPs for 
metastasis-free survival (webappendix pp 22–25). 
Multivariate Cox’s hazard analysis of the TransBig dataset 
(lymph-node negative patients only), which included 
histological grade, tumour size, and oestrogen receptor 
status, indicated that molecular subtypes only added 
independent prognostic information when assigned by 
the Hu SSP for overall survival and metastasis-free 
survival (webappendix pp 22–25). Similar results were 
seen when the 0·1 cutoﬀ  was applied (webappendix 
pp 22–25). For the Wang dataset, no information on 
tumour size and histological grade was available publicly.
To assess associations with outcome of each molecular 
subtype individually, circumventing the few samples 
assigned to each molecular subtype and maximising 
power to detect eﬀ ects, the NKI-295, Wang, and TransBig 
cohorts were combined into one dataset (table 4). This 
analysis indicated that all SSPs were prognostic for 
metastasis-free survival, and they were all prognostic 
for overall survival in the NKI-295 and TransBig cohorts 
(no overall survival data were available for the Wang 
dataset). This ﬁ nding applied to both univariate and 
multivariate analyses, in which outcome was corrected 
for oestrogen receptor status, histological grade, and 
tumour size. Nodal status was not signiﬁ cant in many of 
the models. Since, in many instances, node positivity was 
associated with a slight reduction in hazard, nodal status 
was omitted from these models. Consistent trends were 
seen across SSPs for all molecular subtypes. For example, 
luminal A and normal breast-like subtypes seemed to 
have a reduced event rate relative to the basal group, and 
the luminal B and HER2 subtypes were most likely to be 
associated with a higher event rate than the luminal A 
Figure 3: Molecular subtype classiﬁ cation of TransBig breast cancers and overall survival of patients assigned to molecular subtypes according to three single sample predictors 
ER=oestrogen receptor. SSP=single sample predictor.
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subtype. However, the signiﬁ cance of the association 
between luminal B and normal breast-like groups and 
metastasis-free survival was dependent on the SSP used 
for their assignment (table 4).
Discussion
Our ﬁ ndings show that diﬀ erent SSPs and methods used 
for molecular subtype assignment3–5 produce inconsistent 
results. The number of cases assigned to each molecular 
subtype diﬀ ered depending on the SSP used, and 
agreement for each class was modest (ranging from fair 
to substantial), with the exception of the basal-like 
subtype. These results indicate that assignment of a 
given patient to a molecular subtype other than basal-like 
is strongly dependent on the SSP used and that results 
from studies of a speciﬁ c SSP cannot necessarily be 
generalised. 
However, the association between molecular subtype 
and outcome was fairly consistent, irrespective of the 
SSP used for molecular classiﬁ cation. This ﬁ nding 
suggests that for whole populations, distinct SSPs might 
produce similar associations with outcome. However, 
they do not allocate individual samples to a given 
molecular subtype reproducibly. This result could be 
accounted for in part by associations between molecular 
subtypes and clinico patho logical features linked to 
outcome (webappendix pp 26–29) and with expression 
levels of oestrogen receptor, HER2, and proliferation-
related genes (webappendix pp 38–61). 
Taken together, our observations lend support to the 
idea of a breast cancer molecular classiﬁ cation. However, 
they suggest that the use of current SSPs to allocate cases 
into HER2, luminal A, luminal B, and normal breast-like 
subtypes might be premature for stratiﬁ cation of patients 
or in the context of clinical trials.
The luminal B subtype was not identiﬁ ed reproducibly 
by diﬀ erent SSPs. Since distinction between luminal A 
and luminal B tumours seems to be driven by expression 
of proliferation-related genes,4,14 the absence of 
consistency in allocation of these two subtypes should 
perhaps not come as a surprise. Findings of several 
studies have shown that proliferation in oestrogen 
receptor-positive breast cancers is a continuum,27 and 
allocation of speciﬁ c subgroups (eg, luminal A and B) 
might be arbitrary.
One criticism levelled at molecular classiﬁ cation of 
breast cancer is that normal breast-like tumours could 
be an artifact derived from analysis of tumour 
specimens with a high proportion of normal tissue con-
tamination.4,5,8,14 Indeed, none of the microdissected 
breast cancer specimens with a tumour-cell content of 
at least 90% was assigned to the normal breast-like 
group; however, the cases included in this study were 
all histological grade III, and normal breast-like cancers 
were reported less frequently to be of grade III in the 
NKI-295 series (ﬁ gure 1, webappendix p 27).11 Despite 
several lines of evidence to suggest that the proportion 
of stromal cells has a substantial eﬀ ect on results of 
expression proﬁ ling analysis and on gene classiﬁ ers, 
and that variable amounts of stromal cells in tumours 
introduce a confounding factor in interpretation of 
results of microarray analysis,28 no previous study of 
molecular taxonomy of breast cancer has taken the 
degree of stromal contamination into account. 
Standardisation of tissue composition is needed if 
expression proﬁ ling is to be used for breast cancer 
classiﬁ cation in clinical practice.
Several groups, including ours, have attempted to 
develop surrogate immunohistochemical markers for 
the molecular subtypes of breast cancer as deﬁ ned by 
microarrays;29–31 however, results from these studies 
should be interpreted with caution, in view of the low 
stability of classes other than basal-like. In fact, validity 
of multiple surrogate markers for luminal B subtypes 
(oestrogen receptor (ER)-positive and/or progesterone 
receptor (PR)-positive, and HER2-positive;9,31 or 
ER-positive and/or PR-positive and either HER2-
positive and/or high Ki67 expression)30 remains to be 
established. Even for basal-like breast cancers, no 
international consensus exists about how these tumours 
should be deﬁ ned by immuno histochemistry.32,33 Most 
importantly, data are scarce for direct comparisons 
Sorlie vs Hu SSP Sorlie vs Parker SSP Hu vs Parker SSP
53 grade III invasive ductal carcinomas
Basal-like 0·950 (0·854 to 1·047) 1·000 (1·000 to 1·000) 0·950 (0·854 to 1·047)
HER2 NA NA NA
Luminal A 0·195 (0·054 to 0·336) 0·296 (–0·086 to 0·678) 0·110 (0·002 to 0·217)
Luminal B NA 0·710 (0·513 to 0·908) NA
Normal breast-like NA NA NA
NKI-295 dataset 
Basal-like 0·847 (0·767 to 0·928) 0·962 (0·920 to 1·005) 0·837 (0·754 to 0·920)
HER2 0·482 (0·340 to 0·625) 0·591 (0·468 to 0·715) 0·729 (0·621 to 0·837)
Luminal A 0·530 (0·434 to 0·625) 0·435 (0·325 to 0·545) 0·612 (0·524 to 0·700)
Luminal B 0·390 (0·268 to 0·512) 0·361 (0·242 to 0·480) 0·563 (0·451 to 0·674)
Normal breast-like 0·346 (0·165 to 0·527) 0·348 (0·172 to 0·524) 0·529 (0·347 to 0·710)
Wang dataset
Basal-like 0·928 (0·872 to 0·985) 0·870 (0·795 to 0·945) 0·920 (0·861 to 0·978)
HER2 0·193 (0·046 to 0·341) 0·219 (–0·014 to 0·453) 0·487 (0·329 to 0·645)
Luminal A 0·542 (0·458 to 0·626) 0·384 (0·274 to 0·494) 0·318 (0·242 to 0·393)
Luminal B 0·154 (0·084 to 0·224) 0·305 (0·195 to 0·415) 0·140 (0·080 to 0·200)
Normal breast-like NA NA 0·137 (–0·104 to 0·379)
TransBig dataset
Basal-like 0·827 (0·724 to 0·930) 0·812 (0·706 to 0·918) 0·922 (0·855 to 0·989)
HER2 0·389 (0·198 to 0·580) 0·422 (0·154 to 0·691) 0·496 (0·309 to 0·682)
Luminal A 0·463 (0·362 to 0·563) 0·478 (0·348 to 0·609) 0·473 (0·374 to 0·572)
Luminal B 0·086 (0·019 to 0·153) 0·308 (0·176 to 0·440) 0·145 (0·058 to 0·232)
Normal breast-like NA 0·535 (0·179 to 0·891) NA
Data are κ (95% CI). SSP=single sample predictor. NA=not applicable. 
Table 3: Agreement between single sample predictors for classiﬁ cation of each molecular subtype 
individually 
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between proposed immuno histochemical surrogates 
and microarray-deﬁ ned molecular subtypes.34 
The PAM50 method5 has provided an approach for 
breast cancer molecular classiﬁ cation, which is possibly 
clinically applicable; however, reported agreement 
between the HER2 PAM50-deﬁ ned subtype and HER2 
clinically positive cases (as ascertained by immuno-
histochemistry and FISH) was only moderate.5 Consistent 
with this observation, of cases classiﬁ ed as HER2-positive 
by FDA-approved methods in our in-house dataset of 
grade III invasive ductal carcinomas, just over half were 
assigned to the HER2 molecular subtype by Hu’s SSP, 
whereas all these cases were assigned to the luminal B 
subtype class by the other two SSPs. These results show 
that the HER2 group, as deﬁ ned by microarray gene 
proﬁ ling analysis, does not equate with the clinical 
subgroup of HER2-positive breast cancers. Since patients 
with HER2-positive cancers are eligible for targeted 
treatments (ie, trastuzumab or lapatinib), extensive mis-
assignment of these cases indicates that microarray-
based subtyping should not be used to decide treatment 
for this group of patients.
Although microarray-based gene expression proﬁ ling 
analysis has been reported as able to provide reasonably 
reproducible results for molecular classiﬁ cation of 
breast cancer,3,4 our ﬁ ndings show that without thorough 
standardisation, these tumours cannot be classiﬁ ed 
reliably by this approach. As emphasised by Ioannidis 
and colleagues,35 other investigators might only be able 
to predict molecular subtypes accurately when a detailed 
description of data processing and analytical methods is 
provided. A roadmap similar to the one described for 
development and validation of therapeutically relevant 
genomic classiﬁ ers36 is needed for introduction of breast 
cancer molecular taxonomy in clinical practice. 
Furthermore, careful standardisation of preanalytical 
variables that have a direct eﬀ ect on expression proﬁ les, 
such as stromal component28 and tissue processing,37 
are equally crucial for development of reliable and 
reproducible classiﬁ ers.
Sorlie SSP Hu SSP Parker SSP 
Univariate
hazard ratio 
(95% CI)
p Multivariate
hazard ratio 
(95% CI)
p Univariate
hazard ratio 
(95% CI)
p Multivariate
hazard ratio 
(95% CI)
p Univariate
hazard ratio 
(95% CI)
p Multivariate
hazard ratio 
(95% CI)
p
Metastasis-free survival            
Overall  <0·0001  0·003  <0·0001  0·005  <0·0001  0·001
Basal-like 1  1  1  1  1  1  
HER2 1·44 (0·91–2·26) 0·118 1·82 (1·04–3·2) 0·036 1·1 (0·75–1·63) 0·624 1·77 (1·06–2·95) 0·029 1·03 (0·66–1·62) 0·891 1·59 (0·92–2·76) 0·098
Luminal B 0·97 (0·69–1·37) 0·875 1·38 (0·81–2·35) 0·243 1·54 (1·03–2·31) 0·034 2·02 (1·09–3·73) 0·025 1·04 (0·75–1·43) 0·814 1·49 (0·86–2·59) 0·154
Luminal A 0·54 (0·37–0·78) 0·001 0·73 (0·38–1·4) 0·347 0·6 (0·43–0·83) 0·002 1·01 (0·53–1·91) 0·981 0·44 (0·3–0·65) <0·0001 0·81 (0·42–1·56) 0·524
Normal breast-like 0·38 (0·16–0·89) 0·027 0·61 (0·23–1·61) 0·32 0·45 (0·19–1·06) 0·069 0·83 (0·31–2·21) 0·704 0·42 (0·22–0·81) 0·009 0·88 (0·38–2·05) 0·763
Luminal B vs 
luminal A
1·84 (1·36–2·5) <0·0001 1·99 (1·25–3·16) 0·004 3·27 (2·23–4·79) <0·0001 2·53 (1·45–4·42) 0·001 2·39 (1·7–3·36) <0·0001 1·84 (1·14–2·97) 0·012
HER2 vs luminal A 3·3 (2·1–5·2) <0·0001 2·19 (1·08–4·43) 0·029 1·88 (1·34–2·64) 0·0003 1·59 (0·86–2·93) 0·136 2·48 (1·55–3·94) 0·0001 2·02 (0·97–4·22) 0·062
Histological grade* .. .. 1·2 (0·92–1·55) 0·174 .. .. 1·19 (0·91–1·55) 0·197 .. .. 1·21 (0·93–1·58) 0·148
Oestrogen 
receptor status
.. .. 0·76 (0·49–1·17) 0·219 .. .. 0·64 (0·4–1·04) 0·071 .. .. 0·69 (0·43–1·09) 0·114
Tumour size† .. .. 2·17 (1·4–3·36) 0·0005 .. .. 2·03 (1·32–3·11) 0·001 .. .. 2·04 (1·32–3·16) 0·001
Overall survival
Overall  <0·0001  0·005  <0·0001  0·029  <0·0001  0·007
Basal-like 1  1  1  1  1  1  
HER2 0·99 (0·57–1·7) 0·962 1·51 (0·85–2·66) 0·16 1·01 (0·62–1·65) 0·966 1·42 (0·85–2·38) 0·176 0·86 (0·5–1·47) 0·576 1·26 (0·72–2·22) 0·422
Luminal B 0·7 (0·45–1·09) 0·114 1·1 (0·64–1·91) 0·726 0·86 (0·51–1·43) 0·55 1·53 (0·79–2·96) 0·21 0·7 (0·46–1·07) 0·101 1·2 (0·68–2·12) 0·526
Luminal A 0·26 (0·15–0·45) <0·0001 0·52 (0·25–1·05) 0·069 0·32 (0·2–0·52) <0·0001 0·76 (0·38–1·52) 0·437 0·24 (0·14–0·41) <0·0001 0·52 (0·25–1·09) 0·084
Normal breast-like 0·16 (0·05–0·54) 0·003 0·34 (0·1–1·21) 0·095 0·2 (0·06–0·67) 0·009 0·45 (0·13–1·64) 0·228 0·19 (0·07–0·53) 0·002 0·4 (0·13–1·24) 0·114
Luminal B vs 
luminal A
2·67 (1·61–4·4) 0·0001 2·21 (1·28–3·84) 0·005 3·58 (2·05–6·27) <0·0001 2·73 (1·45–5·13) 0·002 2·94 (1·76–4·9) <0·0001 2·25 (1·28–3·98) 0·005
HER2 vs luminal A 4·49 (2·45–8·24) <0·0001 2·84 (1·24–6·52) 0·014 3·31 (2·03–5·41) <0·0001 1·78 (0·9–3·54) 0·099 4·01 (2·14–7·49) <0·0001 2·7 (1·09–6·7) 0·032
Histological grade* .. .. 1·23 (0·92–1·66) 0·168 .. .. 1·24 (0·91–1·68) 0·172 .. .. 1·21 (0·9–1·63) 0·205
Oestrogen 
receptor status
.. .. 0·62 (0·39–0·98) 0·041 .. .. 0·52 (0·31–0·89) 0·017 .. .. 0·57 (0·34–0·94) 0·026
Tumour size† .. .. 2·11 (1·3–3·41) 0·002 .. .. 1·94 (1·21–3·11) 0·006 .. .. 1·93 (1·19–3·13) 0·007
SSP=single sample predictor. *Ordinal 1, 2, or 3. †Log (tumour size [mm]). 
Table 4: Univariate and multivariate Cox’s regression analysis of overall and metastasis-free survival for the NKI-295, Wang, and TransBig datasets combined 
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Limitations of our study include use of retrospectively 
accrued cohorts, the fact that three cohorts were retrieved 
from public repositories and some clinicopathological 
features were not available in one of the cohorts (ie, 
tumour size and grade in the Wang dataset),17 and varied 
follow-up length in diﬀ erent datasets.16–18 These limitations 
are also applicable to other studies of molecular taxonomy 
of breast cancer.1–3
For translation of current knowledge on the molecular 
features of breast cancer, the mechanisms of action of 
chemotherapy agents, and the availability of many 
compounds that target speciﬁ c molecular pathways or 
networks, molecular classiﬁ cations should have direct 
functional implications and be predictive of response to 
speciﬁ c therapeutic agents, rather than being descriptive 
and prognostic.8,38,39 This requirement is likely to need an 
integrative approach, combining descriptive data from 
suﬃ  ciently powered cohorts40 and many sources, including 
clinicopathological features, massively parallel DNA and 
RNA sequencing, and proteomics, with detailed functional 
data from large panels of cancer models (eg, high through-
put RNA interference and chemical screens).8,38,39,41,42
In conclusion, although SSPs identify molecular 
subtypes with similar trends for association with 
outcome, they do not assign reliably the same patients 
to the same molecular subtypes. Before molecular 
subtype classiﬁ cation can be incorporated into routine 
clinical practice and treatment decision making, 
stringent standardisation of methodologies and 
deﬁ nitions for identiﬁ cation of breast cancer molecular 
subtypes is needed.  
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